The updated guideline for estrogen and progesterone receptor (ER/PgR) testing in breast cancer, published jointly today by the College of American Pathologists and the American Society of Clinical Oncology, reaffirms much of the original guidance and has more specific recommendations for handling and reporting cases with low ER expression.
More...